ARCHIVES

Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

New Seer Report Says Five Year Relative Survival At 49 Per Cent Over all, 50 Per Cent For White

November 30, 1984

News Analysis: Generic Drug Industry’s Efforts to Eliminate Shortages Raises Antitrust Law Questions

April 27, 2012

NIH Director Collins Publishes Third Book About Faith In God

March 5, 2010

FDA Approves Medication For Smoking Cessation

May 26, 2006

NCAB TO Reconsider Decision Not To Fund Diet Fit Trial

October 20, 1989

Senate Votes Down Attempt to Cut NCI Funds $100 Million

October 3, 1975